oncos-102
Biologicalexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01598129)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- oncos-102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05561491 | Phase 2 | Dec 31, 2022 | Agenus Inc., Targovax ASA, Vanderbilt University |
| NCT02963831 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | Cancer Research Institute, Ludwig Institute for Cancer Research, MedImmune, Targovax ASA |
| NCT03003676 | Phase 1 | Dec 1, 2016 | Targovax ASA |
| NCT02879669 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | Targovax ASA, Theradex |
| NCT01598129 | Phase 1 | Apr 1, 2012 | Targovax ASA |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Targovax ASA | For profit | 5 | 4 | 2 | 2012 |
| Agenus Inc. | For profit | 1 | 0 | 1 | 2022 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2017 |
| MedImmune | For profit | 1 | 0 | 1 | 2017 |
| Theradex | For profit | 1 | 0 | 1 | 2016 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2022 |
7 organizations
Page 1 / 1